Findings on Drug Research Reported by Investigators at Yale University (Mir-33 Deletion In Hepatocytes Attenuates Masld-mash-hcc Progression).

Researchers at Yale University conducted a study on the role of hepatic miR-33 in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD) and hepatocellular carcinoma (HCC). The study found that deletion of miR-33 in hepatocytes improved various aspects of the disease, including steatosis and inflammation, reducing the progression to MASH, fibrosis, and HCC. The results suggest that suppressing hepatic miR-33 could be an effective therapeutic approach to mitigate the development of MASLD, MASH, and HCC in obesity. Funding for the research was provided by the National Institutes of Health (NIH) - USA, American Heart Association, American Diabetes Association, and the Spanish Government. [Extracted from the article]